Literature DB >> 10579497

A systematic review of the treatment of depression with antidepressant drugs in patients who also have a physical illness.

D Gill1, S Hatcher.   

Abstract

To determine whether antidepressants are clinically effective and acceptable for the treatment of depression in people who also have a physical illness. The method used was a systematic review of all randomised controlled trials (found by computer and hand searches) comparing any antidepressant drug with placebo or no treatment, in depressed adults with a specified physical disorder. The main outcome measures are numbers of individuals who recover/improve at the end of the trial and, as a proxy for treatment acceptability, numbers who complete treatment. 18 studies were included, covering 838 patients with a range of physical diseases. 6 studies used SSRIs, 3 atypical antidepressants, and the remainder tricyclics. Patients treated with antidepressants were significantly more likely to improve than those given placebo: about 4 patients would need to be treated with antidepressants to produce one recovery from depression which would not have occurred had they been given placebo (NNT 4.2, 95% CI 3.2-6.4). Most antidepressants (tricyclics and SSRIs together, 15 trials) produced a small but significant increase in dropout (OR 1.66, 95% CI 1.14-2.40. NNH 9.8, 95% CI 5.4-42.9). The "atypical" antidepressant mianserin produced significantly less dropout than placebo. Trends towards tricyclics being more effective than SSRIs, but also more likely to produce dropout were noted. The review provides evidence that antidepressants, significantly more frequently than either placebo or no treatment, cause improvement in depression in patients with a wide range of physical diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579497     DOI: 10.1016/s0022-3999(99)00020-3

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  12 in total

1.  Multimorbidity, Depression, and Mortality in Primary Care: Randomized Clinical Trial of an Evidence-Based Depression Care Management Program on Mortality Risk.

Authors:  Joseph J Gallo; Seungyoung Hwang; Jin Hui Joo; Hillary R Bogner; Knashawn H Morales; Martha L Bruce; Charles F Reynolds
Journal:  J Gen Intern Med       Date:  2015-10-02       Impact factor: 5.128

2.  Depression after myocardial infarction is a risk factor for declining health related quality of life and increased disability and cardiac complaints at 12 months.

Authors:  P de Jonge; T A Spijkerman; R H S van den Brink; J Ormel
Journal:  Heart       Date:  2005-05-12       Impact factor: 5.994

3.  A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.

Authors:  Charles H Bombardier; Jesse R Fann; Catherine S Wilson; Allen W Heinemann; J Scott Richards; Ann Marie Warren; Larry Brooks; Catherine A Warms; Nancy R Temkin; Denise G Tate
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

4.  Patterns of medical resource and psychotropic medicine use among adult depressed managed behavioral health patients.

Authors:  Francisca Azocar; Loren M McCarter; Brian J Cuffel; Thomas W Croghan
Journal:  J Behav Health Serv Res       Date:  2004 Jan-Mar       Impact factor: 1.505

5.  Depression in Asthma: Prevalence and Clinical Implications.

Authors:  Tanya A. Zielinski; E Sherwood Brown; Vicki A. Nejtek; David A. Khan; Jacob J. Moore; A John Rush
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-10

6.  Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer.

Authors:  S Suzuki; T Akechi; M Kobayashi; K Taniguchi; K Goto; S Sasaki; S Tsugane; Y Nishiwaki; H Miyaoka; Y Uchitomi
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

7.  More evidence that depressive symptoms predict mortality in COPD patients: is type D personality an alternative explanation?

Authors:  Jacob N de Voogd; Johan B Wempe; Klaas Postema; Eric van Sonderen; Adelita V Ranchor; James C Coyne; Robbert Sanderman
Journal:  Ann Behav Med       Date:  2009-10

8.  Underdiagnosis of depression in HIV: who are we missing?

Authors:  Steven M Asch; Amy M Kilbourne; Allen L Gifford; M Audrey Burnam; Barbara Turner; Martin F Shapiro; Samuel A Bozzette
Journal:  J Gen Intern Med       Date:  2003-06       Impact factor: 5.128

9.  Epidemiology and treatment of post-stroke depression.

Authors:  Stefano Paolucci
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

10.  The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity.

Authors:  T N Wise; C G Wiltse; D V Iosifescu; M Sheridan; J Y Xu; J Raskin
Journal:  Int J Clin Pract       Date:  2007-06-22       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.